Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
25
05
2022
accepted:
06
11
2022
pmc-release:
01
03
2024
pubmed:
30
11
2022
medline:
4
3
2023
entrez:
29
11
2022
Statut:
ppublish
Résumé
Emerging evidence suggests that melanocortin neuropeptides-specifically adrenocorticotropic hormone-offer a novel, steroidogenic-independent therapeutic modality for membranous nephropathy (MN). The molecular mechanism underlying this beneficial effect, however, remains largely elusive. To investigate whether melanocortins modulate humoral immunity, the authors induced passive Heymann nephritis, a model of human MN, in wild-type and melanocortin 1 receptor (MC1R) knockout rats and treated them with melanocortin agents. Additional rats received adoptive transfer of bone marrow-derived cells beforehand from wild-type or MC1R knockout rats. The findings indicate that MC1R signaling plays a key role in negative modulation of B-cell activation and thereby suppresses humoral immune responses in passive Heymann nephritis, and suggest that MC1R signaling might offer a novel B cell-targeted therapeutic strategy for MN. Emerging evidence suggests that the pituitary neuropeptide melanocortins-specifically, adrenocorticotropic hormone-offer a novel nonsteroidogenic therapeutic modality for membranous nephropathy (MN). However, the mechanism(s) of action remains elusive. To investigate whether melanocortins modulate humoral immunity, we induced passive Heymann nephritis (PHN), a model of MN, in wild-type (WT) and melanocortin 1 receptor (MC1R) knockout (KO) rats. We treated the animals with melanocortin agents-repository corticotropin injection, the nonsteroidogenic pan-melanocortin receptor agonist [Nle 4 , DPhe 7 ]-α-melanocyte stimulating hormone, the selective MC1R agonist MS05, vehicle gel, or phosphate-buffered saline-and evaluated kidney function, histology, and molecular changes. Additional rats received adoptive transfer of syngeneic bone marrow-derived cells beforehand from WT or MC1R KO rats. KO of MC1R worsened PHN and this was associated with increased deposition of autologous immunoglobulin G (IgG) and complement C5b-9 in glomeruli and higher circulating levels of autologous IgG-evidence of a sensitized humoral immune response. Melanocortin therapy ameliorated PHN in WT rats, coinciding with reduced glomerular deposition of autologous IgG and C5b -9. The beneficial efficacy of melanocortins was blunted in KO rats but restored by adoptive transfer of syngeneic bone marrow-derived cells derived from WT rats. Mechanistically, MC1R was expressed in B lymphocytes and was negatively associated with B cell activation. MC1R agonism triggered the expression of microphthalmia-associated transcription factor in activated B cells in a cAMP-dependent mode and also repressed the expression of interferon regulatory factor 4 (a lymphoid transcription factor essential for B-cell development and maturation), resulting in suppressed plasma cell differentiation and IgG production. MC1R signaling negatively modulates B cell activation and suppresses humoral immune responses in PHN, suggesting that MC1R signaling might offer a novel therapeutic target for MN.
Sections du résumé
SIGNIFICANCE STATEMENT
Emerging evidence suggests that melanocortin neuropeptides-specifically adrenocorticotropic hormone-offer a novel, steroidogenic-independent therapeutic modality for membranous nephropathy (MN). The molecular mechanism underlying this beneficial effect, however, remains largely elusive. To investigate whether melanocortins modulate humoral immunity, the authors induced passive Heymann nephritis, a model of human MN, in wild-type and melanocortin 1 receptor (MC1R) knockout rats and treated them with melanocortin agents. Additional rats received adoptive transfer of bone marrow-derived cells beforehand from wild-type or MC1R knockout rats. The findings indicate that MC1R signaling plays a key role in negative modulation of B-cell activation and thereby suppresses humoral immune responses in passive Heymann nephritis, and suggest that MC1R signaling might offer a novel B cell-targeted therapeutic strategy for MN.
BACKGROUND
Emerging evidence suggests that the pituitary neuropeptide melanocortins-specifically, adrenocorticotropic hormone-offer a novel nonsteroidogenic therapeutic modality for membranous nephropathy (MN). However, the mechanism(s) of action remains elusive.
METHODS
To investigate whether melanocortins modulate humoral immunity, we induced passive Heymann nephritis (PHN), a model of MN, in wild-type (WT) and melanocortin 1 receptor (MC1R) knockout (KO) rats. We treated the animals with melanocortin agents-repository corticotropin injection, the nonsteroidogenic pan-melanocortin receptor agonist [Nle 4 , DPhe 7 ]-α-melanocyte stimulating hormone, the selective MC1R agonist MS05, vehicle gel, or phosphate-buffered saline-and evaluated kidney function, histology, and molecular changes. Additional rats received adoptive transfer of syngeneic bone marrow-derived cells beforehand from WT or MC1R KO rats.
RESULTS
KO of MC1R worsened PHN and this was associated with increased deposition of autologous immunoglobulin G (IgG) and complement C5b-9 in glomeruli and higher circulating levels of autologous IgG-evidence of a sensitized humoral immune response. Melanocortin therapy ameliorated PHN in WT rats, coinciding with reduced glomerular deposition of autologous IgG and C5b -9. The beneficial efficacy of melanocortins was blunted in KO rats but restored by adoptive transfer of syngeneic bone marrow-derived cells derived from WT rats. Mechanistically, MC1R was expressed in B lymphocytes and was negatively associated with B cell activation. MC1R agonism triggered the expression of microphthalmia-associated transcription factor in activated B cells in a cAMP-dependent mode and also repressed the expression of interferon regulatory factor 4 (a lymphoid transcription factor essential for B-cell development and maturation), resulting in suppressed plasma cell differentiation and IgG production.
CONCLUSIONS
MC1R signaling negatively modulates B cell activation and suppresses humoral immune responses in PHN, suggesting that MC1R signaling might offer a novel therapeutic target for MN.
Identifiants
pubmed: 36446431
pii: 00001751-202303000-00013
doi: 10.1681/ASN.2022050605
pmc: PMC10103281
doi:
Substances chimiques
Adrenocorticotropic Hormone
9002-60-2
alpha-MSH
581-05-5
Complement Membrane Attack Complex
0
Immunoglobulin G
0
Melanocortins
0
Receptor, Melanocortin, Type 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-481Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Beck LH Jr, Salant DJ. Membranous nephropathy: from models to man. J Clin Invest. 2014;124(6):2307-2314. doi: 10.1172/JCI72270
doi: 10.1172/JCI72270
Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. doi: 10.1038/s41572-021-00303-z
doi: 10.1038/s41572-021-00303-z
Beck LH Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/nejmoa0810457
doi: 10.1056/nejmoa0810457
Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2011;8(2):122-128. doi: 10.1038/nrneph.2011.190
doi: 10.1038/nrneph.2011.190
Metcoff J, Rance CP, Kelsey WM, Nakasone N, Janeway CA. Adrenocorticotrophic hormone (ACTH) therapy of the nephrotic syndrome in children. Pediatrics. 1952;10(5):543-566. doi: 10.1542/peds.10.5.543
doi: 10.1542/peds.10.5.543
Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis. 2014;21(2):134-151. doi: 10.1053/j.ackd.2013.09.004
doi: 10.1053/j.ackd.2013.09.004
Cameron JS, Healy MJR, Adu D; on behalf of the MRC Glomerulonephritis Working Party. The medical research council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med. 1990;74(274):133-156. doi: 10.1093/oxfordjournals.qjmed.a068422
doi: 10.1093/oxfordjournals.qjmed.a068422
Cattran DC, Delmore T, Roscoe J, et al. the Toronto Glomerulonephritis Study Group. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med. 1989;320(4):210-215. doi: 10.1056/nejm198901263200403
doi: 10.1056/nejm198901263200403
Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47(2):233-240. doi: 10.1053/j.ajkd.2005.10.016
doi: 10.1053/j.ajkd.2005.10.016
Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570-1577. doi: 10.1093/ndt/gfu069
doi: 10.1093/ndt/gfu069
Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999;56(4):1534-1543. doi: 10.1046/j.1523-1755.1999.00675.x
doi: 10.1046/j.1523-1755.1999.00675.x
Bomback AS, Canetta PA, Beck Jr LH, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58-67. doi: 10.1159/000339287
doi: 10.1159/000339287
Jefferson JA, Pippin JW, Shankland SJ. Experimental models of membranous nephropathy. Drug Discov Today Dis Models. 2010;7(1–2):27-33. doi: 10.1016/j.ddmod.2010.11.001
doi: 10.1016/j.ddmod.2010.11.001
Wensink D, Wagenmakers MA, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021;14(2):151-160. doi: 10.1080/17512433.2021.1879638
doi: 10.1080/17512433.2021.1879638
Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21(8):1290-1298. doi: 10.1681/ASN.2009101025
doi: 10.1681/ASN.2009101025
Elvin J, Buvall L, Lindskog Jonsson A, et al. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. Am J Physiol Renal Physiol. 2016;310(9):F846-F856. doi: 10.1152/ajprenal.00231.2015 2
doi: 10.1152/ajprenal.00231.2015
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-2308. doi: 10.1038/nprot.2013.143
doi: 10.1038/nprot.2013.143
Li C, Ge Y, Dworkin L, Peng A, Gong R. The beta isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy. J Pathol. 2016;239(1):23-35. doi: 10.1002/path.4692
doi: 10.1002/path.4692
Hayes K, Warner E, Bollinger C, Wright D, Fitch RM. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model. BMC Nephrol. 2020;21(1):226. doi: 10.1186/s12882-020-01879-6
doi: 10.1186/s12882-020-01879-6
Pösel C, Möller K, Fröhlich W, Schulz I, Boltze J, Wagner D-C. Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One 2012;7(12):e50293. doi: 10.1371/journal.pone.0050293
doi: 10.1371/journal.pone.0050293
Muraca M, Ferraresso C, Vilei MT, et al. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. Gut. 2007;56(12):1725-1735. doi: 10.1136/gut.2007.127969
doi: 10.1136/gut.2007.127969
Souza D, Gregorio B, Benchimol M, Braga F. Evaluation of the glomerular filtration barrier by electron microscopy. In: MILOS JANECEK RK, editor. Modern Electron Microscopy in Physical and Life Sciences. London: IntechOpen; 2016.
Meezan E, Brendel K, Ulreich J, Carlson EC. Properties of a pure metabolically active glomerular preparation from rat kidneys. I. Isolation. J Pharmacol Exp Ther. 1973;187(2):332-341.
Rush BM, Small SA, Stolz DB, Tan RJ. An efficient sieving method to isolate intact glomeruli from adult rat kidney. J Vis Exp 2018;(141). doi: 10.3791/58162
doi: 10.3791/58162
McDonald JH, Delaware Uo. Handbook of Biological Statistics. Sparky House Publishing; 2009.
Si J, Ge Y, Zhuang S, Juan Wang L, Chen S, Gong R. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int. 2013;83(4):635-646. doi: 10.1038/ki.2012.447
doi: 10.1038/ki.2012.447
Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi: 10.1210/er.2007-0027
doi: 10.1210/er.2007-0027
Fabre T, Barron AMS, Christensen SM, et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation in human and murine liver and lung fibrosis. bioRxiv. 2002.01.498017. doi: 10.1101/2022.07.01.498017
doi: 10.1101/2022.07.01.498017
Benko AL, Wright AD, Sunyer T, Kovacs WJ, Olsen NJ. Pituitary neuropeptides and B lymphocyte function. Scand J Immunol. 2021;94:e13041. doi: 10.1111/sji.13041
doi: 10.1111/sji.13041
Groves CJ, Carrell J, Grady R, et al. CD19-positive antibody-secreting cells provide immune memory. Blood Adv. 2018;2(22):3163-3176. doi: 10.1182/bloodadvances.2017015172
doi: 10.1182/bloodadvances.2017015172
Herraiz C, Garcia-Borron JC, Jimenez-Cervantes C, Olivares C. MC1R signaling. Intracellular partners and pathophysiological implications. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10):2448-2461. doi: 10.1016/j.bbadis.2017.02.027
doi: 10.1016/j.bbadis.2017.02.027
Lee SH, Lee YM, Lee JH, Kim DK. Involvement of MITF-A, an alternative isoform of mi transcription factor, on the expression of tryptase gene in human mast cells. Exp Mol Med. 2010;42(5):366-375. doi: 10.3858/emm.2010.42.5.038
doi: 10.3858/emm.2010.42.5.038
Choudhary P, Gutteridge A, Impey E, et al. Targeting the cAMP and transforming growth factor-β pathway increases proliferation to promote re-epithelialization of human stem cell-derived retinal pigment epithelium. Stem Cell Transl Med. 2016;5(7):925-937. doi: 10.5966/sctm.2015-0247
doi: 10.5966/sctm.2015-0247
Tshori S, Gilon D, Beeri R, et al. Transcription factor MITF regulates cardiac growth and hypertrophy. J Clin Invest. 2006;116(10):2673-2681. doi: 10.1172/jci27643
doi: 10.1172/jci27643
Lin L, Gerth AJ, Peng SL. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J Exp Med. 2004;200(1):115-122. doi: 10.1084/jem.20040612
doi: 10.1084/jem.20040612
Oppezzo A, Rosselli F. The underestimated role of the microphthalmia-associated transcription factor (MiTF) in normal and pathological haematopoiesis. Cell Biosci. 2021;11(1):18. doi: 10.1186/s13578-021-00529-0
doi: 10.1186/s13578-021-00529-0
Honey K. MITF's calming influence. Nat Rev Immunol. 2004;4(8):582. doi: 10.1038/nri1419
doi: 10.1038/nri1419
Monaco G, Lee B, Xu W, et al. RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cel Rep. 2019;26(6):1627-1640.e7. doi: 10.1016/j.celrep.2019.01.041
doi: 10.1016/j.celrep.2019.01.041
Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773-782. doi: 10.1038/ni1357
doi: 10.1038/ni1357
Gao Y, Usha Raj J. Effects of SQ 22536, an adenylyl cyclase inhibitor, on isoproterenol-induced cyclic AMP elevation and relaxation in newborn ovine pulmonary veins. Eur J Pharmacol. 2002;436(3):227-233. doi: 10.1016/s0014-2999(02)01261-x
doi: 10.1016/s0014-2999(02)01261-x
Lai PF, Tribe RM, Johnson MR. Differential impact of acute and prolonged cAMP agonist exposure on protein kinase A activation and human myometrium contractile activity. J Physiol. 2016;594(21):6369-6393. doi: 10.1113/jp272320
doi: 10.1113/jp272320
Grieco P, Balse PM, Weinberg D, MacNeil T, Hruby VJ. D-amino acid scan of gamma-melanocyte-stimulating hormone: importance of trp(8) on human MC3 receptor selectivity. J Med Chem. 2000;43(26):4998-5002. doi: 10.1021/jm000211e
doi: 10.1021/jm000211e
Bergwall L, Wallentin H, Elvin J, et al. Amplification of the melanocortin-1 receptor in nephrotic syndrome identifies a target for podocyte cytoskeleton stabilization. Sci Rep. 2018;8(1):15731. doi: 10.1038/s41598-018-34004-7
doi: 10.1038/s41598-018-34004-7
Wang Y, Eng DG, Kaverina NV, et al. Global transcriptomic changes occur in aged mouse podocytes. Kidney Int. 2020;98(5):1160-1173. doi: 10.1016/j.kint.2020.05.052
doi: 10.1016/j.kint.2020.05.052
Spicer ST, Tran GT, Killingsworth MC, et al. Induction of passive Heymann nephritis in complement component 6-deficient PVG rats. J Immunol. 2007;179(1):172-178. doi: 10.4049/jimmunol.179.1.172
doi: 10.4049/jimmunol.179.1.172
Chang M, Chen B, Shaffner J, Dworkin LD, Gong R. Melanocortin system in kidney homeostasis and disease: novel therapeutic opportunities. Front Physiol. 2021;12:651236. doi: 10.3389/fphys.2021.651236
doi: 10.3389/fphys.2021.651236
Jonsson AL, Granqvist A, Elvin J, Johansson ME, Haraldsson B, Nystrom J. Effects of melanocortin 1 receptor agonists in experimental nephropathies. PLoS One 2014;9:e87816. doi: 10.1371/journal.pone.0087816
doi: 10.1371/journal.pone.0087816
Qiao Y, Berg AL, Wang P, et al. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci Rep. 2016;6(1):27589. doi: 10.1038/srep27589
doi: 10.1038/srep27589
Qiao Y, Wang P, Chang M, et al. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Clin Sci. 2020;134(7):695-710. doi: 10.1042/cs20200016
doi: 10.1042/cs20200016
Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol. 2007;7(1):52-63. doi: 10.1038/nri1984
doi: 10.1038/nri1984
Botte DAC, Noronha IL, Malheiros DMAC, Peixoto TV, de Mello SBV. Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model. Clin Exp Immunol. 2014;177(2):381-390. doi: 10.1111/cei.12336
doi: 10.1111/cei.12336
Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-315. doi: 10.1038/s41584-019-0211-0
doi: 10.1038/s41584-019-0211-0
Decker DA, Grant C, Oh L, Becker PM, Young Young, Jordan S. Immunomodulatory effects of H.P. Acthar gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014; 24(8):802-812. doi: 10.1177/0961203314531840
doi: 10.1177/0961203314531840
Olsen NJ, Decker DA, Higgins P, et al. Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro. Arthritis Res Ther. 2015;17(1):300. doi: 10.1186/s13075-015-0823-y
doi: 10.1186/s13075-015-0823-y
Muraguchi A, Miyazaki K, Kehrl JH, Fauci AS. Inhibition of human B cell activation by diterpine forskolin: interference with B cell growth factor-induced G1 to S transition of the B cell cycle. J Immunol. 1984;133(3):1283-1287.
Mykicki N, Herrmann AM, Schwab N, et al. Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease. Sci Transl Med. 2016;8(362):362ra146. doi: 10.1126/scitranslmed.aaf8732
doi: 10.1126/scitranslmed.aaf8732
Hartzell S, Sanchez-Russo L, Pecchio IP, et al. Repository corticotropin injections promote clinical remission and regulatory T cell expansion in membranous nephropathy. Kidney Int Rep. 2021;6(9):2491-2495. doi: 10.1016/j.ekir.2021.06.010
doi: 10.1016/j.ekir.2021.06.010